Back to results
US 12,747,301 B2Granted
Use of LANCL1 and antibodies thereof as a diagnostic and therapeutic target for the management and treatment of cancer
AssigneeThe University of Hong Kong
InventorsIrene Oi Lin Lui Ng, Yu Man Tsui
Life of this patent
Estimating the term…
Abstract
The subject invention pertains to antibodies that target LANCL1. The anti-LANCL1 antibodies can be used in methods of treating cancer, including hepatocellular carcinoma. The anti-LANCL1 antibody can be used as a therapeutic regimen for treatment or as part of a combination treatment. Further, the anti-LANCL1 antibodies may also be useful for targeting the tumor initiating cells.
Claims3
A method of inhibiting cancer cell proliferation in a subject, comprising administering to the subject an antibody that specifically binds to LANCL1, wherein the antibody binds to SEQ ID NO:
- 8, 12, or 13, wherein the cancer cell is a liver tumor initiating cell, wherein the cancer cell is a hepatocellular carcinoma cell, wherein the antibody is an Abnova H00010314-A01 antibody, Sigma-Aldrich HPA034994 antibody, or a Novus Biologicals NBP1-81796 antibody.
Dependencies are inferred from the claim text.